<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335361">
  <stage>Registered</stage>
  <submitdate>12/04/2010</submitdate>
  <approvaldate>10/06/2010</approvaldate>
  <actrnumber>ACTRN12610000476033</actrnumber>
  <trial_identification>
    <studytitle>Acetazolamide in X-linked Retinoschisis</studytitle>
    <scientifictitle>The effect of Acetazolamide on visual acuity, retinal thickness and macular cyst size in patients with X-linked retinoschisis</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>Nil</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>X-linked Retinoschisis</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral acetazolamide 200mg twice a day &gt;60kg or 125mg twice &lt;60kg. 

Participants allocated to the acetazolamide/placebo study arm will receive acetazolamide first, followed by placebo, and vice versa in the placebo/acetazolamide. The duration of acetazolamide will be three months. The mode of administration is oral capsule.

Cross over occurs at 3 months following first dose of treatment. Measurements at are done at 0, 3 and 6months. Hence no "wash-out" period is required.</interventions>
    <comparator>placebo: 20mg microcellulose oral pill, twice a day for 3 months.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Best corrected visual acuity using Snellen and Log MAR Chart</outcome>
      <timepoint>0, 3 and 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Retinal thickness using optical coherence tomography (OCT)</outcome>
      <timepoint>0, 3 and 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Macular cyst size using optical coherence tomography (OCT)</outcome>
      <timepoint>0, 3 and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Ni</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Patients with X-linked retinoschisis diagnosis and stable ocular fixation with no clinically significant media opacities.

There will be no age restrictions</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-	Hypersensitivity to sulphonamides and sulphonamide derivatives
- Women who are pregnant
- People in existing dependent or unequal relationships
- People highly dependent on medical care
- Aboriginal and/or Torres Striait Islander People
- People who may be involved in illegal activity
- People with an intellectual or mental impairment
- People whose primary language is other than English.
- A refractive error greater than Â±6 diopters (D) sphere
- Uveitis
- Optic neuropathy
- The presence of nystagmus or any other retinal diseases affecting the macula other than retinoschisis
- A recent history (&lt;6months) of intraocular surgery, and poor optical coherent tomography (OCT) image quality.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All patients with X-linked retinoschisis diagnosis will be identified from the Save Sight Institute computerised medical records and invited to participate in the study. Patients will be sent a letter from the researchers inviting them to participate in the clinical trial. The letter contains details of the study including: aims, study procedure and method, risks, benefits, cost, voluntary participation and confidentiality.

Allocation is not concealed</concealment>
    <sequence>Simple randomisation by using coin-tossing.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>Nil</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>21/06/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Sydney</primarysponsorname>
    <primarysponsoraddress>The University of Sydney
Sydney
NSW 2006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>The University of Sydney</fundingname>
      <fundingaddress>Sydney Eye Hospital Campus
8 Macquarie Street Sydney NSW 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>X-linked retinoschisis is a genetic eye disorder characterised by abnormal splitting of the retina, resulting in a loss of vision. Currently there is no treatment available for X-linked retinoschisis. However, an improvement in sight has been reported following the use of topical and oral acetazolamide in people with X-linked retinoschisis. Hence, the objective of this study is to investigate whether oral acetazolamide improves the sight of people with X-linked retinoschisis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service Ethic Review Committee (Royal Prince Alfred Zone)</ethicname>
      <ethicaddress>Research Development Office
Level 3, Building 92
Royal Prince Alfred Hospital
Missenden Road
CAMPERDOWN NSW 2050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>26/05/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr John Grigg</name>
      <address>Save Sight Institute
Sydney Eye Hospital Campus
8 Macquarie Street
Sydney NSW 2000</address>
      <phone>+61 2 9382 7302</phone>
      <fax />
      <email>jrgrigg@bigpond.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michael Wei</name>
      <address>182/116 Maroubra Road Maroubra NSW 2035</address>
      <phone>+61 434020435</phone>
      <fax />
      <email>michaelclwei@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michael Wei</name>
      <address>182/116 Maroubra Road Maroubra NSW 2035</address>
      <phone>+61 434020435</phone>
      <fax />
      <email>michaelclwei@gmail.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>